We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 1SAN market cap is 115.76B. The company's latest EPS is EUR 4.3109 and P/E is 21.44.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 36.13B | 36.04B | 37.76B | 43B | 43.07B |
| Operating Income | 3.13B | 6.42B | 7.71B | 10B | 7.19B |
| Net Income | 2.81B | 12.29B | 6.22B | 8.37B | 5.4B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 112.74B | 114.41B | 120.24B | 126.72B | 126.46B |
| Total Liabilities | 53.63B | 51.16B | 51.21B | 51.57B | 52.11B |
| Total Equity | 59.11B | 63.25B | 69.03B | 75.15B | 74.35B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 7.74B | 7.42B | 10.52B | 10.53B | 10.26B |
| Investing | -1.21B | 3.62B | -7.3B | -2.08B | -6.2B |
| Financing | -4.19B | -6.49B | -7.06B | -5.82B | -8.05B |
| Market Cap | 115.76B |
| Price to Earnings Ratio | 21.44 |
| Price to Sales Ratio | 2.69 |
| Price to Cash Ratio | 13.29 |
| Price to Book Ratio | 1.56 |
| Dividend Yield | 4.07% |
| Shares Outstanding | 1.25B |
| Average Volume (1 week) | 1.16k |
| Average Volume (1 Month) | 812 |
| 52 Week Change | 5.13% |
| 52 Week High | 107.96 |
| 52 Week Low | 83.40 |
| Spread (Intraday) | 0.08 (0.09%) |
| Company Name | Sanofi |
| Address |
46, avenue de la grande armee paris, paris 75017 |
| Website | https://www.sanofi.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
